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Abstract
Clear cell renal cell carcinoma (ccRCC) provides a tumor paradigm for the integration of genetics,
molecular biology, therapeutic target validation, and the introduction of high impact treatment
strategies. Most cases of sporadic as well as familial ccRCC acquire somatic inactivating mutations
of the von Hippel-Lindau tumor suppressor gene, VHL. pVHL, VHL gene product and a protein
member of the E3 ubiquitin ligase family, acts in normal cells to direct the degradation and clearance
of the hypoxia inducible factor (HIFα) transcription factor family, such that in its absence, as in
ccRCC, the HIF proteins stabilize, accumulate to supraphysiologic levels, and activate the
transcription of genes such as vascular endothelial growth factor (VEGF) and platelet derived growth
factor (PDGF), which contributes substantially to the physiology of the tumor, and has been assessed
indirectly as a prognostic factor. Molecularly targeted therapy blocking components of this pathway
has been successfully introduced to the clinic with a substantive impact on clinical parameters of
RCC. This review will examine the regulation of these molecular pathways in RCC and discuss the
impact on the clinical management of patients with RCC.
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VHL Mutation and Renal Cell Carcinoma
Germline mutations of the von Hippel-Lindau (VHL) tumor suppressor gene located at
chromosome 3p25 cause autosomal dominant hereditary von Hippel-Lindau familial cancer
syndrome characterized by an increased risk of tumor development in multiple organs
including hemangioblastoma of the central nervous system and retina, pheochromocytoma and
paraganglioma, and clear cell renal cell carcinoma (ccRCC) [1-3] The VHL disease is highly
penetrant, affecting nearly 90% of individuals by the age of 55 years old. The gene for VHL
disease (VHL) was identified in 1993 with the identification of germline carriers of mutations
[4*]. Although with rare exception patients inherit one mutant copy of the gene, all
manifestations of the disease require the loss or inactivation of the wild type allele, by a classical
Knudsen two-hit mechanism [5,6].
Sporadic ccRCC parallels the genetic mechanism of tumor initiation seen in VHL disease with
a high frequency of cytogenetic losses at 3p25 as well as somatic VHL mutations which can
be detected in 60 to 90% of patients with this cancer [7-9]. RCC is a heterogeneous disease,
and VHL mutations are not observed in nonclear cell (papillary or chromophobe) histologies,
however, tumors described as histologically mixed variants including a component of clear
cell may harbor these mutations.
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VHL Gene Regulation and Activity
VHL: regulation of protein levels
The VHL gene, located on a simple locus and composed of 3 exons, encodes for a short protein
(pVHL) with potent tumor suppressive activity as demonstrated by the introduction of a wild
type VHL cDNA which represses the growth of tumors in immunocompromised mice [10]. No
known mechanisms of alternative splicing occur, but an alternate N-terminal truncated version
is produced as a result of in-frame internal ATG 54 amino acid downstream of the traditionally
recognized start site, producing a 19kD product in addition to the usual 30kD pVHL product
[11]. This second gene product retains the tumor suppressive function of the full length protein,
but its specific role is not known. The relative presence of the two pVHL products appears to
be of little consequence in the promotion of cancer, as disease causing mutations are rarely if
ever identified localizing to this N-terminal 54 amino acid region (Figure 1). Further, although
the murine and human genes are highly conserved, the amino terminal region is exclusively
quite divergent, adding support to the tumor suppressor activity of the protein to be relegated
to the central and C terminal portions [12]. Post-translational modifications are not known to
contribute to the stability or overall level of the protein.
The pVHL protein is expressed in the cytoplasm of cells in the tissues broadly affected by VHL
disease, specifically kidney tubule, pancreas, adrenal gland, liver parenchyma, and various
neural tissues as well as epithelial tissues not characteristically involved in the disease such as
the thyroid, intestine, and bronchi [2,3]. During embryogenesis the protein is expressed in all
three germ layers, and later shows strong expression in the kidney, testis, central nervous
system, and lung [13].
As mentioned above, the loss of one copy of the VHL allele in ccRCC occurs commonly as a
loss of heterozygosity event. This may occur through genetic deletion, either small deletions
impacting only a small part of the locus or the large chromosomal aberrations as in the
cytogenetic 3p abnormalities. Alternatively, the VHL locus is highly susceptible to methylation,
which results in genetic silence and functional loss of pVHL, although the allele is wild type.
The majority of primary mutations observed in the VHL gene are gene editing events—
frameshift insertions and deletions, nonsense mutations which result in the premature insertion
of a stop codon, or missense mutations which may interfere with an important protein
interaction domain. Intrinsically, the pVHL protein is quite stable. However, missense
mutations may also confer instability, resulting in a functional and/or quantitative loss of pVHL
activity [14].
VHL: protein domains
As alluded above, the pVHL protein is structurally simple, composed primarily of protein-
protein interaction domains (Figure 1). The N terminus of the protein is largely undefined, and
retains no known function essential for the tumor suppressive activity of pVHL. The remainder
of the protein is composed of an α domain which promotes the interaction of pVHL with the
Elongin B and Elongin C members of the E3 ubiquitin ligase complex [15]. This region,
composed of residues 156-193, contains a subdomain of residues 157-172 which is a frequent
site of missense mutations in VHL disease and is sufficient to bind Elongin C in vitro, although
the remaining residues form additional helices which stabilize this interaction in vivo. The β
domain directs the interaction of pVHL with substrates of the E3 ubiquitin ligase. This domain,
encompassing variably residues 63-155 has been shown to be essential for the interaction with
both atypical protein kinase C and the hydroxylated forms of the hypoxia inducible factor (HIF)
[16,17]. Portions of this domain can also independently mediate tumor growth suppression
[18].
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Further regulation of pVHL protein interaction occurs through the process of Neddylation
which impacts the ability of pVHL to interact with fibronectin, but does not abrogate the
activity as an E3 ubiquitin ligase [19]. Indeed, engagement of pVHL with hydroxylated HIF
promotes further Neddylation of the Cullin-2 protein and accelerates the activity of the E3
ligase to support HIF ubiquitylation [20].
VHL: regulation of HIF
pVHL performs several putative cellular activities, but has been extensively studied for its role
in regulating the cellular response to extrinsic oxygen signals. pVHL functions as the substrate
recognition component of an E3 ubiquitin ligase complex that also contains Elongin B, Elongin
C, Ring box protein 1 (Rbx1), and Cullin 2 (Cul2) [21]. The pVHL protein’s β domain targets
substrates for ubiquitination and degradation by the 26S proteasome [7-9]. Known and putative
substrates of pVHL E3 ligase activity include atypical protein kinase C (aPKC),
hyperphosphorylated Rbp1, VHL deubiquitinating enzymes (VDU)-1 and -2, and HIFα
subunits. The latter notable group of proteins targeted in this way by pVHL is a family of potent
transcription factors including HIF1α and HIF2α which are induced in response to hypoxia as
seen in the deepest tissues where physiologic levels of oxygen fall to 3-5% or in pathological
conditions of ischemia [22]. In the presence of oxygen, one (or both) of two prolyl residues in
the HIFα oxygen degradation domain (ODD) is hydroxylated by members of the EglN family
[23-25]. Hydroxylated HIFα is recognized by pVHL, recruited to the E3 ubiquitin ligase
complex, polyubiquitinated, and targeted for proteasomal degradation [26]. When the VHL
gene is lost or mutated in such a way that either participation in the E3 ubiquitin ligase complex
or interaction with the HIFα substrates is disrupted, these transcription factors are not degraded
and accumulate to stably high levels to dimerize with HIFβ to form transcriptionally active
HIF (Figure 2).
Other HIF family members regulated by pVHL include HIF3α, a group of alternative spliced
isoforms sharing the ODD domain without known physiologic or pathologic roles in either
hypoxia regulation or cancer. The specific cellular biological processes or tissue specific
contexts which govern the distinctions between HIF1α and HIF2α upregulation remain
incompletely understood. Some of this distinction is guided by tissue restriction in the regional
expression of these two genes, as observed in mouse tissues [27]. Additionally, the activities
of the individual HIF factors may vary in the pathologic state. In VHL null ccRCC, cyclin D1,
transforming growth factor α, and vascular endothelial growth factor (VEGF) have been shown
to respond specifically to HIF-2α [28]. Thus, the distinct profiles of HIF family members
stabilized within a tumor may have important implications for both the origin and the behavior
of the tumor.
HIF-related effects of VHL loss
The transcriptional targets of HIF activation are extensive and include essentially the complete
set of factors required for a physiologic cellular response to restrictions of oxygen supply
[29]. Transcriptionally active HIF is a heterodimer consisting of an unstable α subunit and a
stable β subunit which further complex with the CREB binding protein (CBP) and p300 to
activate transcription of genes containing specific promoter elements. The repertoire of genes
induced by the independent HIF family members is an overlapping, but not identical set of
genes involved in the cellular response to oxygen deprivation [30-32]. HIF target gene
activation (Figure 3) encompasses targets with a wide range of roles including important tumor
promoting actions such as angiogenesis, evasion of cell death, cellular metabolism, and cell
differentiation [29,31]. The activation of these targets contributes to the adaptive cellular
survival of a hypoxic insult and tumor-promoting properties underlying most ccRCC.
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As described above, VHL inactivation in RCC stabilizes the HIF factors within the tumor cells.
The HIF transcription factor complex has been demonstrated to transcriptionally induce the
expression of genes involved in angiogenesis, anaerobic glucose metabolism, cell motility and
metastasis, growth and survival, apoptosis, and telomere maintenance [31]. Notable genes
induced by HIF involved in angiogenesis are VEGF, platelet derived growth factor (PDGF),
as well as other pro-angiogenic factors such as angiopoietin-4 (Ang4) [33,34]. These factors
promote the proliferation, migration, and maturation of endothelial cells and pericytes
supporting the recruitment of vessels or neoangiogenesis necessary to restore blood supply to
an ischemic region, or in the case of RCC, this causes the rampant, disorganized proliferation
of vessels in this highly vascular tumor. Additional factors include proteins involved in
promoting the cellular switch to anaerobic glycolysis such as the glucose transporter, Glut1,
enzymes of glucose metabolism such as hexokinase (HK) and lactate dehydrogenase (LDH),
and the lactate transporter, MCT-4 [35-37]. This hypoxic repertoire of gene upregulation likely
contributes to the highly glycolytic phenotype of RCC, even in the presence of abundant oxygen
with which to perform oxidative phosphorylation for energy generation [38].
The distinction between RCCs which have high levels of only HIF1α, only HIF2α, or a
combination of these two HIFα factors is an active area of investigation and not clearly
understood. Mutations in VHL can specifically impact the balance of the different HIF factors
[39]. Evidence from specific VHL disease-causing mutations which predispose to distinct
patterns of tumor development (VHL disease subtypes 2A, 2B, 2C, and Chuvash Polycythemia
—each of which carries a high risk for developing pheochromocytoma and greater or lesser
penetrance for the hemangioblastoma and RCC phenotypes of the disease) suggests that the
degree of HIF2α stabilization contributes substantially to the risk of RCC (Table 1) [40*].
Additionally, increasing evidence suggests that the dosage of HIF factors may influence the
disease predisposition as evidenced by individuals who carry a very subtle alteration in the
carboxyterminus of the VHL gene are predisposed to the autosomal recessive development of
congenital polycythemia induced as a result of a small but not insignificant increase in HIF
levels and a steady elevation of serum erythropoietin [41-45]. This prediction is further born
out in an animal model of Chuvash polycythemia in which a homozygous mutation in the
murine VHL allele confers a limited degree of HIF stabilization and elevated erythropoietin
levels with concordant elevations in measured hematocrits in these animals [46].
Much evidence points toward VHL associated HIF stabilization as an integral component of
the renal cancer phenotype and a key to the maintenance of tumor growth. Indeed, the most
significant evidence supporting this comes from an elegant analysis in which renal carcinoma
cells lacking VHL and exclusively stabilizing HIF-2α were found to lose the capability to grow
as a xenograft when HIF-2α levels were suppressed by shRNA [47]. These observations
pinpoint HIF-2α as the potentially critical factor in renal tumorigenesis, and suggest its
proclivity for development as a therapeutic target.
VHL: non-HIF activities
A variety of cellular effects caused by the loss of pVHL cannot be explained exclusively by
the effects on HIF factor regulation. As an example, a protein involved in cellular polarity and
cellular growth, atypical protein kinase C lambda was found to be ubiquitinated by the pVHL-
containing E3 ubiquitin ligase complex VCB. This ubiquitination could be observed in both
cell free and cellular ubiquitination systems and demonstrated dependence on pVHL [48]. This
activity may play a critical role in the development of pheochromocytoma in VHL disease
[49].
One interesting activity of pVHL which has recently received a great amount of attention is a
role in the formation and maintenance of the primary cilia, a cellular structure essential to the
determination of cell polarity. pVHL interacts with a complex that directs the orientation of
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microtubules and can be localized to the primary cilium. Loss of pVHL results in
disorganization of newly formed microtubules and precludes the formation of the primary
cilium [50,51*]. pVHL has been demonstrated to play a role in the formation of the primary
cilium, and failure to form this cellular appendage promotes the formation of cysts in the kidney
as well as other organs [52,53].
pVHL is also necessary for the organization of intercellular junctions and control of cellular
permeability as well as the maintenance and determination of cell polarity [54,55]. Similarly,
pVHL interactions with various members of extracellular proteins are widely observed largely
independent of HIF regulation. Such interactions include directed binding to hydroxylated
collagen IV [56,57]. Evidence suggests additionally that pVHL operates along other pathways
promoting extracellular matrix assembly. pVHL interacts with fibronectin and a functional
pVHL appears to be required to maintain functions in constructing or maintaining the
extracellular matrix. As an example, a wild type copy of VHL is essential for the complete
assembly of the fibronectin extracellular matrix [58]. In particular, an analysis of VHL mutants
with and without destabilizing effects on HIF regulation demonstrated that pVHL appears to
play a role in fibronectin deposition independent of functions regulating HIF stability [39,
59]. In support of this prediction, HIF-directed shRNA, which does abrogate cell growth in
xenograft form has minimal impact on the development of the extra cellular matrix [60]. In
addition to fibronectin matrix formation, pVHL has been found to have a role in actin and
vinculin assembly and functions to restrict cellular motility [61]. This aspect of pVHL activity
presents a potentially important tumor suppressive function and efforts are underway to explore
the role of disordered extracellular matrix in the development of RCC.
VHL Gene Mutation in RCC
RCC characteristics resulting from VHL inactivation
Histologically, VHL inactivation contributes substantially to characteristic aspects of ccRCC.
The defining feature of ccRCC is the histologic appearance of large cells with abundant
cytoplasm packed with glycogen and neutral lipids. The high level of glucose metabolism
observed in ccRCC likely accounts for the accumulation of immense quantities of glycogen,
and further, the neutral lipid may be contributed to by the expression of the HIF target gene
adipose differentiation related peptide (ADRP), a cell surface lipid transport molecule which
may account for the cytoplasmic neutral lipid accumulation for which ccRCC was named
[62]. Additional tumor specific metabolic characteristics can be correlated to HIF target gene
activation such as the elevated lactate levels within RCC likely related to the high rates of
glucose metabolism, and impairment of the oxidative phosphorylation process for generating
ATP.
VHL gene mutation and HIF target gene activation can also contribute to the patient-specific
physiology of RCC. Specifically, the paraneoplastic polycythemia can be directly associated
with systemic elevated erythropoietin liberated inappropriately from the tumor. Polycythemia
is observed only in a small percentage of patients with RCC, likely due to competing factors
which contribute to blood loss and iron deficiency anemia or the anemia of chronic disease.
This syndrome, however, should not be overlooked as it requires treatment with phlebotomy
if the tumor is not amenable to surgical resection, and its presence related to ccRCC provides
an indication to initiate systemic therapy for metastatic disease.
Interestingly, the expanding list of HIF target gene activation accounts for much of the unique
attributes of conventional RCC: ADRP, neutral lipid accumulation and clear cell histology;
VEGF and other angiokines, vascularity; erythropoietin, paraneoplastic polycythemia.
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Biomarkers of VHL inactivation
Clinically, the presence of clear cell histology has served as a proxy for VHL inactivation and
disregulation of the HIFα factors for several years. However, although this association is
common, the rapidly expanding use of sophisticated molecularly targeted therapy demands
improved understanding of an individual patient’s disease. As our understanding of the genetics
behind RCC expands, so does our ability to use molecular markers as indicators of disease
prognosis.
Carbonic anhydrase IX
Much attention has been focused on a subset of genes induced in response to HIF activation
as surrogate markers of VHL inactivation. These transcriptionally regulated genes are selected
based on high fidelity with the primary molecular event, either VHL loss or HIFα stabilization,
and limited expression in non-cancer cells. These HIF regulated target genes may be developed
as indicators of disease prognosis or therapeutic targets in their own right. The antigen carbonic
anhydrase IX (CAIX, also called G250) was identified through a massive tissue microarray
screen investigating prognostic factors for RCC. CAIX is a transcriptional target of the HIF-
mediated transcriptional response to hypoxia or VHL loss [63-65]. CAIX is an immediate target
of HIF activation and provides a convenient marker for clear cell histology tumors and has
been associated with a favorable prognosis [66]. There may be some limitations to use this
biomarker as a general test for RCC due to the high level expression overall, however, as a
predictor of response to interleukin-2, this marker shows promise in identifying the subset of
patients who are likely to respond well to this treatment and is the subject of a major clinical
trial effort [67,68]. The role this protein plays in ccRCC remains uncertain, although this gene
may participate in regulating the tumor intracellular pH [69]. Immunostaining for the CAIX
protein in renal carcinomas provides a potentially straightforward molecular prognostication
test which could be rapidly implemented into current clinical prognostic schemas. For patients
with high risk resected RCC, low CAIX expression predicted a poor outcome measured in rates
of disease recurrence. Overall expression of CAIX decreased with development of metastasis
and decreased CAIX levels are associated with shorter survival in metastatic RCC [70]. In a
specific population of patients undergoing treatment with interleukin-2, CAIX, along with
PTEN, was found to be an independent prognostic factor in predicting complete response to
this treatment [71]. Further validation of this prognostic biomarker, however, is required before
this test can be implemented as a tool for clinical decision making.
Additionally, as a potential tumor marker with cancer cell specificity, CAIX has been
considered as a potential therapeutic target. A humanized antibody directed against CAIX has
been developed and is currently undergoing investigation in clinical trials.
CXCL12 and CXCR4
A pair of targets of HIF1α transcriptional activation which have been implicated as biomarkers
are the chemokine stromal derived factor-1 (SDF-1/CXCL12) and its receptor CXCR4
involved in directing cell migration. CXCR4 expression has been shown to correlate with
metastatic potential in xenograft models of human RCC. Further, neutralization of CXCL12
using monoclonal antibodies in mouse models prevented RCC metastasis while sparing effects
on tumor cell proliferation, apoptosis, or tumor angiogenesis, suggesting that CXCL12 and
CXCR4 may play an important role in directing tumor cell migration and ultimately RCC
propensity to form metastasis [72]. As biomarkers of VHL inactivation, CXCL12 and CXCR4
demonstrated an association with poor RCC-specific survival, which is consistent with their
association with promoting tumor cell migration[73,74]. However, reconciling the discrepancy
between CXCL12/CXCR4 and CAIX as independently negative and positive predictors of
outcome remains difficult. As surrogates of VHL inactivation should not equally predispose to
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poor or good risk disease, these findings may suggest deviations in the spectrum of HIF target
genes activated in an individual tumor or other differences in tumors beyond VHL inactivation
and HIF expression. This conundrum may prove impenetrable with the currently available data
as the presence of VHL mutation may impact disease prognosis differently for patients with
localized versus metastatic disease, and such prognostic markers must ultimately be viewed as
independent risk factors for the time being requiring validation in multivariate studies.
VHL Mutation in RCC: Prognostic Implications
VHL mutation: surgical implications
As put forward above, evidence from studies specifically examining prognostic associations
with VHL mutations suggests that the presence of an inactivating VHL mutation may associate
with improved survival for patients with resectable disease undergoing nephrectomy. Thus,
VHL mutation may be associated with a slower growing tumor, with more limited potential to
have a priori metastatic disease at the time of resection, but may predispose to a more
aggressive or difficult disease course for the later stages of disease. Interestingly, this
correlation was most statistically significant for those patients with higher stage tumors going
forward with a planned definitive surgical resection (stage III patients) as well as patients whose
tumor was of a histologically high grade or those individuals presenting with symptomatic
localized disease [75]. In this investigation, patients with stage IV disease undergoing
debulking nephrectomy did not have the same positive correlation between VHL mutation and
disease outcome. An independent analysis specifically examining of loss of function versus
missense mutations in VHL, however, failed to demonstrate significant associations with
prognosis except for a potential association of a specific missense mutation with the
development of metastatic disease [76].
VHL mutation: implications for the development of targeted therapy
Somatic inactivation of the VHL gene is the most frequent genetic event observed in ccRCC,
and it was the elucidation of this signaling pathway that led to the recent revolution in RCC
targeted therapy. This review has already discussed the mechanism which directs the
dysregulation of VEGF expression. In 2003, an important proof of principle study was
undertaken to investigate the potential for clinical activity of therapies directed against one
aspect of HIF disregulation, VEGF. In this phase II analysis, a humanized VEGF monoclonal
antibody bevacizumab (©Avastin, Genentec, Inc.) was examined in previously treated patients
with metastatic RCC. Patients were randomized to placebo or one of two dose levels groups,
and patients receiving the higher dosage were found to have an improvement in progression
free survival which was statistically significant compared to either the placebo or the low
dosage group [77*]. Subsequently, a randomized placebo controlled study investigating the
addition of bevacizumab to interferon in comparison to interferon alone (AVOREN)
demonstrated an improvement in progression free survival from 5.4 months to 10.2 months as
well as an improvement in tumor shrinkage [78]. Results from a similarly designed CALGB
investigation are anticipated soon, and will lend additional information in the further
exploitation of VEGF as a target for renal cell carcinoma therapy [79].
On the heels of this important study was the development of receptor tyrosine kinase inhibitors
which target the VEGF receptor family, effectively neutralizing the signaling pathways
activated as a result of growth factor engagement of the cognate receptor. The first of these
small molecule inhibitors, sorafenib (©Nexavar, Bayer and Onyx Pharmaceutical), targets a
panel of kinases including the VEGF receptor family, PDGF receptor, and raf kinase. This
small molecule inhibitor was first investigated in RCC in a randomized discontinuation study
which also demonstrated an improvement in progression free survival [80]. This prompted
further analysis in the pivotal placebo controlled randomized phase III trial for patients with
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metastatic ccRCC who had developed progressive disease after prior cytokine therapy showing
an improvement in progression free survival which led to the approval of this drug by the
Federal Drug Administration (FDA) in December 2005 [81**]. Another VEGF receptor and
PDGF receptor inhibitor, sunitinib (©Sutent, Pfizer Oncology) with an overlapping, but
distinct portfolio of kinase inhibitory substrates was examined first in a pair of phase II studies
in pretreated patients, and subsequently in a randomized phase III study comparing sunitinib
to interferon (©Intron A, Shering-Plough) [82**,83]. This landmark study demonstrated an
impressive partial response rate of 31%, prolongation of progression free survival, and a trend
in favor of improving overall survival, the benchmark of successful intervention in RCC.
Sunitinib was approved for advanced RCC in January 2006. The impact of these new agents
in the management of RCC cannot be understated, and the activity in this highly treatment
resistant disease underscores the importance of this signaling pathway in RCC.
As further evidence that HIF activation may play a central role in RCC, a third agent,
temsirolimus (©Torisel, Wyeth, Inc.) has been developed and recently approved for RCC based
on a randomized phase III study which demonstrated an improvement in overall survival when
compared to interferon or interferon in combination with temsirolimus [84**]. This derivative
of rapamycin acts as an inhibitor of the mammalian target of rapamycin (mTOR) signaling
pathway, which also intersects the HIF pathway by preventing mTOR-promoted protein
translation of HIF via the S6 kinase. Thus, in the mTOR inhibited state HIF levels cannot be
stabilized because the primary production of HIF is limited, as has been demonstrated elegantly
in an in vitro study of HIF accumulation in response to hypoxic stimulation with and without
rapamycin [85].
Multiple new drugs are on the horizon for development in RCC based on the biology of
VHL inactivation in these tumors. Specific attempts to inhibit HIF accumulation and stability
have been explored in a variety of ways (Figure 4). The inhibition of heat shock protein, HSP90,
provides an opportunity to eliminate an important chaperone of HIF-1α which can promote its
degradation [86,87]. Other strategies of potential interest include the development of the natural
compound, chetomin, as an inhibitor of HIF interaction with the co-factor p300, which is
essential for HIF-mediated transcription [88]. A similar approach to high throughput screens
of small molecule inhibitors has been applied to targeting cells lacking pVHL expression, with
the compound Chromomycin A3 emerging as an agent with specific activity against these cells
[89*]. Finally, further approaches to target genes activated on RCC as a result of HIF activation
include the development of strategies to target CAIX, a HIF target discussed above as a
potential biomarker of good risk disease. Efforts to target cells expressing CAIX have been
moved into the clinical arena [90,91]. These and other approaches to target components of the
VHL loss/HIF stabilization/HIF target gene activation pathway have great potential for
advancing the care of RCC patients in the near future, but remain to be validated in either
accurate animal models or human disease.
VHL mutation: implications for response to therapy
The implications of RCC histology in each of the current molecularly targeted therapies
remains an open question. Only the phase III study with temsirolimus included nonclear cell
histologies, and this study found a benefit for patients independent of the histology, and by
assumption the genetic history of the tumor. Evidence for activity of the multitargeted kinase
inhibitors in the nonclear cell histologies of RCC remains limited to data from either the early
phase clinical trials or compassionate use registry studies in place while the drugs were awaiting
formal approval. It is clear that all of these new agents have activity in ccRCC, but the weight
of evidence is strongest for the use of temsirolimus in those patients with papillary or
chromophobe type RCC which are not associated with VHL mutations.
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Furthermore, the prognostic relevance of somatic VHL alteration and the resultant stabilization
of HIF1α and HIF2α have not been defined in the treatment of metastatic disease. It has long
been appreciated that non-clear cell histologies of RCC were poorly responsive to
immunotherapies. However, specific associations correlating response to treatment with
VHL mutation have long been sought, although only suggestions of increased responsiveness
to cytokine therapy among patients with missense VHL mutations as compared to functional
VHL deletions have been observed [76].
In the era of targeted therapeutics, an enormously practical question looms. Are patients with
VHL mutation-associated RCC tumors more likely to respond to the emerging therapeutic
strategies? In one single institution series, 43 patients with metastatic RCC who received
therapy with interferon-α plus bevacizumab (©Avastin, Genentech, Inc.), sunitinib (©Sutent,
Pfizer, Inc.) or axitinib (Pfizer, Inc.) were examined for the correlation between activation
status of the VHL gene and tumor response, time to tumor progression and overall survival, of
whom 26 patients (60%) had evidence of VHL mutation or promoter methylation. In this
preliminary study, an absolute improvement in objective response from 35% to 48% was
observed, and further, a nearly doubling of time to tumor progression (from 7.4 months to 13.3
months) was observed in patients carrying a significant VHL mutation compared to those
individuals for whom no VHL mutation was identified [92]. This preliminary observation
warrants continued investigation, as VHL mutation status may provide an important predictive
marker for response to VEGF-targeted therapy as well as future novel therapeutic strategies in
RCC. An expanded set of patients from this series continues to demonstrate a trend in favor of
response among tumors with an inactivating VHL mutation, although tumors without VHL
mutation can clearly achieve responses to these agents [93].
Expert Commentary
The discoveries culminated in the elucidation of pVHL regulatory pathway have at this point
defined RCC diagnosis, physiology, and treatment. Prior to the breakthroughs linking VHL
mutation with HIF activation, angiogenesis, and tumor maintenance, little attention was paid
to the histologic description of the tumor, and prognostic algorithms were almost entirely
measuring the impact of the tumor on the individual patient rather than that of the genetic lesion
on the behavior of the individual tumor. This view has undergone a radical evolution, with
tumor histology taking priority status in determining a course of therapy. Knowledge of this
pathway has provided a direct avenue for therapeutic development, with now three new FDA
approved drugs providing rational therapeutic options, with dramatic shifts in expectations
facing patients with both metastatic and limited disease. Currently, oncologists suffer from an
embarrassment of riches, with a variety of active compounds and limited data to guide the
therapeutic decision for an individual patient. Expanded studies of biomarkers to guide
prognosis and therapeutic selection remain essential to bring this new era of RCC to the next
level.
Five year view
At this time, the framework and magnitude of these molecular pathways has only just become
evident as a diagnostic and therapeutic basis. As we learn more about the important aspects of
HIF dysregulation related to such nuances as ratios of the different family members, levels of
the stabilized proteins, and the individual portfolios of activated transcriptional targets, we will
likely encounter essential biomarkers which impact the prognostic algorithm. Some of these
molecular signatures will likely be incorporated into the next generation of prognostic factors.
Further, all known molecular aspects of VHL loss are currently undergoing an exhaustive
evaluation for the development of novel targeted agents for cancer treatment. Additionally,
combinations of the currently approved agents are actively undergoing test to evaluate whether
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maximal blockade of this signaling pathway can be achieved with available drugs. Although
large definitive studies are unlikely to be feasible, smaller clinical trials to address issues of
sequential or combination use, and expanded use of biomarkers stands poised to guide
therapeutic decision making based on pathologic, genetic, or molecular attributes of an
individual tumor in the next step toward the integration of individualized medicine into day-
to-day oncology decisions.
Key issues
• VHL mutation is a common feature of clear cell renal cell carcinoma.
• VHL inactivation imparts all or most of its impact on RCC via HIF stabilization.
• VHL inactivation and upregulation of the HIF target gene CAIX is a favorable risk
factor for surgically respectable RCC.
• Although the recent surge in the development of targeted therapies evolved as a result
of understanding the effects of VHL inactivation, it remains unclear what role VHL
mutations play in predicting responses to these agents.
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Figure 1. pVHL functional domains
pVHL has two main domains: β domain and α domain. pVHL contains 213 amino-acids (30
kDa). A second major VHL gene product arises by internal translation initiation from the codon
ATG 54 amino acid methionine, producing a 160 amino-acid protein (19 kDa). The α domain
contains a subdomain of residues 157-172, a frequent site of missense mutations and binding
to Elongin C. The β domain directs the interaction of pVHL with substrates of the E3 ubiquitin
ligase, containing residues 91-113 binding to HIF.
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Figure 2. pVHL activity in physiologic and pathologic states
HIFα subunit stabilization as a result of either hypoxia or VHL mutation leads to dimerize with
HIF1β to form active HIF to transcriptional activate a panel of hypoxia responsive genes.
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Figure 3. HIF1a and HIF2a regulate independent, but overlapping panels of target genes
Common target genes include genes involved in pH regulation, cell migration, angiogenesis,
nutrient (glucose and lipid) uptake, and red blood cell production. Exclusive hypoxia response
targets of HIF-1 include enzymes involved in glycolysis, whereas Oct4, an important
transcription factor in maintaining the differentiation state of the cell, is an independent target
of HIF-2. HK, hexokinase; LDH, lactate dehydrogenase; PDHK, pyruvate dehydrogenase
kinase; CAIX, carbonic anhydrase IX; SDF-1(CXCL12), stromal cell derived factor-1;
CXCR4, chemokine receptor 4; VEGF, vascular endothelial growth factor; PDGF, platelet
derived growth factor; Ang4, angiopoietin 4; ADRP, adipose differentiation related peptide;
Glut-1, glucose transporter 1; EPO, erythropoietin; Oct4, octamer binding protein 4.
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Figure 4. Strategies to target the VHL/HIF pathway for therapeutic intervention
Multiple strategies are currently being employed and explored to inhibit the pathological
activation of this pathway. Red X indicates a strategy discussed in the review as a potential or
actively used approach for treating patients with disease caused as a result of VHL loss or
aberrant HIF activation. These include: inhibition of mTOR, preventing protein synthesis of
HIF, inhibition of HSP90, an important chaperone involved in HIF stability during
cytoplasmic/nuclear shuttling, inhibition of cell growth in cells lacking VHL, inhibition of HIF
interaction with transcriptional cofactors p300 and CBP, direct inhibition of targets of HIF
activation, and inhibition of signaling receptors activated downstream of HIF transcriptional
activation.
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Table 1
VHL disease subtypes and correlation with HIF 2α levels
Mutations associated with each subtype of disease have been linked to differential regulation of the HIF2α.
VHL Disease
Subtype Hemangioblastoma Pheochromocytoma ccRCC HIF 2α Levels
Type 1 + Low + +++
Type 2A + + Low +
Type 2B + + + ++
Type 2C − + − −
Chuvash
Polycythemia − − − +/−
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